Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

Significant progress is being made in the fight against lung cancer, according to a new study from the American Lung ...

Despite improvements in survival and early detection rates, Pennsylvania still faces challenges with high smoking rates and ...

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ...

Please provide your email address to receive an email when new articles are posted on . Five-year lung cancer survival has improved with increased screening, which has led to more early-stage ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Connecticut is the second-best state in the country for lung cancer survival and screening, but the American Lung Association in Connecticut says more can still be done. The State of Lung Cancer ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...